Hillhurst Biopharmaceuticals said it’s been awarded $6.3 million to fund a Phase 2a clinical study to test the efficacy of HBI-002, its low-dose liquid formulation of carbon monoxide, in preserving dopaminergic neurons, those that are lost to Parkinson’s disease, with the goal of slowing or stopping disease progression. The…
The first three patients treated with ANPD001, a cell therapy for Parkinson’s disease, showed reduced motor symptoms and improved daily functioning over six months, without any serious side effects. That’s according to early data from the Phase 1/2a ASPIRO (NCT06344026) study, an open-label clinical trial testing the…
A small molecule called NK036 — which inhibits USP30, an enzyme that counters the removal of damaged mitochondria from nerve cells in Parkinson’s disease — fits tightly into its target, suggesting it may have a strong and lasting effect as a treatment for the neurological condition, a new study…
Listening to rhythm-based cues while walking not only builds lasting walking habits, but also helps people with Parkinson’s disease walk more, at a greater intensity, and more steadily than walking on their own. These are the findings of a clinical study (NCT05421624) that tested MR-005, a digital tool…
Ring-shaped small proteins called macrocyclic peptides — originally developed to target proteins linked to diabetes and Alzheimer’s disease — have now been shown in a laboratory to also prevent alpha-synuclein from forming the hallmark toxic clumps observed in Parkinson’s disease. That’s according to researchers from the Technical University of…
Inflammation visible in brain scans of people in the early stages of Parkinson’s disease may serve as an early indicator of dementia risk and offer a promising target for interventions aimed at preventing cognitive decline, a study suggests. “[O]ur findings suggest that significant … neuroinflammation in early [Parkinson’s] might…
Two undergraduate students from Rice University in Houston have designed an affordable, vibrating glove that they say lets patients feel vibrations in their fingertips to retrain misfiring neurons (nerve cells) in the brain — a hallmark of Parkinson’s disease — and help them regain motor control. The work by…
Nearly 1 in 8 people diagnosed with Parkinson’s disease in Finland within the past couple of decades were later given a different diagnosis, usually within two years, underscoring the need for better clinical criteria and regular checkups. When Parkinson’s and dementia with Lewy bodies, a neurodegenerative disease also…
The Van Andel Institute (VAI) — founded nearly three decades ago to advance biomedical research and science education — is awarding its 2025 Jay Van Andel Award to a University of Pittsburgh professor for his work on environmental factors in Parkinson’s disease. This year’s award will be presented…
The investigational liquid therapy ND0612 — an around-the-clock supply of levodopa/carbidopa infused via a pump under the skin — provides more stable motor control in people with Parkinson’s disease who experience motor fluctuations than standard immediate-release levodopa/carbidopa. That’s according to data from the randomized portion of the…
Get regular updates to your inbox.
